Spinosyn A derivatives as ASS1 activators and tumor inhibitors.Other primary literatureHumanActiveBioorganic & medicinal chemistry letters2026
Huang XY, Liu XH, Xu N, et al.
Arginine restriction exploits DNMT3B-ASS1-driven arginine auxotrophy and mTORC1-suppressed autophagy to overcome niraparib resistance in ovarian cancer.Other primary literatureHuman & animalActiveCancer letters2026
Wang H, Wang X, Zhang W, et al.
DDIT3, OTUB2, and ASS1 regulate arginine biosynthesis in colorectal cancer cells under arginine deficiency.Other primary literatureHuman & animalActiveCell reports2026
Li M, Zhang J, Zhang H, et al.
ASS1 Promotes Colorectal Cancer Immune Evasion Through CPT1A-Mediated S100A10 Succinylation.Other primary literatureHuman & animalActiveFrontiers in bioscience (Landmark edition)2026
Sun L, Fu D, Zhang H
ZFPL1 Promotes Colorectal Cancer Progression by Stabilizing ASS1 to Drive the Urea Cycle and M2 Macrophage-Mediated Metastatic Colonization.Other primary literatureHuman & animalActiveAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Qian X, Xie C, Zhang B, et al.
ASS1 enhances anoikis resistance via AMPK/CPT1A-mediated fatty acid metabolism in ovarian cancer.Other primary literatureHuman & animalActiveCancer letters2025
Feng X, Ji Z, Fan X, et al.
Advances in the impact of ASS1 dysregulation on metabolic reprogramming of tumor cells.ReviewHuman & animalActiveCellular signalling2025
Xia J, Liu W, Ni Y, et al.
ASS1 inhibits liver cancer by promoting CAD ubiquitination and reversing the urea cycle and pyrimidine synthesis imbalance.Other primary literatureHuman & animalActiveHepatology communications2025
Ming Z, Luo T, Zou Z, et al.
Etoposide-induced protein 2.4 homolog promotes argininosuccinate synthase 1 and cancer cell survival upon arginine deprivation.Other primary literatureHumanActiveCellular & molecular biology letters2025
Vo VTA, Tran LN, Bui TT, et al.
Sestrin3 confers resistance to recombinant human arginase in small cell lung cancer by activating Akt/mTOR/ASS1 axis.Other primary literatureHuman & animalActivePloS one2025
Zhang Z, Lin Z, Li W, et al.
Evodiamine Inhibits Colorectal Cancer by Downregulating ASS1 via Wnt/β-Catenin/c-MYC Pathway to Block Arginine Synthesis.Other primary literatureUnknownActivePharmaceuticals (Basel, Switzerland)2025
Wang H, Deng H, He J, et al.
LM2I leads to CAD ubiquitination and liver cancer suppression through activation of ASS1.Other primary literatureHuman & animalActiveActa biochimica et biophysica Sinica2025
Ming Z, Luo T, Zou Z, et al.
β-Sitosterol targets ASS1 for Nrf2 ubiquitin-dependent degradation, inducing ROS-mediated apoptosis via the PTEN/PI3K/AKT signaling pathway in ovarian cancer.Other primary literatureHumanActiveFree radical biology & medicine2024
Wang H, Liu J, Zhang Z, et al.
ASS1 inhibits triple-negative breast cancer by regulating PHGDH stability and de novo serine synthesis.Other primary literatureHuman & animalActiveCell death & disease2024
Luo W, Zou Z, Nie Y, et al.
ASS1-Mediated Reductive Carboxylation of Cytosolic Glutamine Confers Ferroptosis Resistance in Cancer Cells.Other primary literatureHumanActiveCancer research2023
Hu Q, Dai J, Zhang Z, et al.
A pan-cancer analysis of the role of argininosuccinate synthase 1 in human tumors.Other primary literatureUnknownActiveFrontiers in oncology2023
Ding Q, Li R, Wang Q, et al.
PGAM1 regulation of ASS1 contributes to the progression of breast cancer through the cAMP/AMPK/CEBPB pathway.Other primary literatureHumanActiveMolecular oncology2022
Liu M, Li R, Wang M, et al.
ASS1 regulates immune microenvironment via CXCL8 signaling in ovarian cancer.Other primary literatureHuman & animalActiveBiochemical and biophysical research communications2022
Feng X, Ji Z, Yang G
Argininosuccinate synthase 1, arginine deprivation therapy and cancer management.ReviewUnknownActiveFrontiers in pharmacology2022
Sun N, Zhao X
Therapeutic targeting of argininosuccinate synthase 1 (ASS1)-deficient pulmonary fibrosis.Other primary literatureHuman & animalActiveMolecular therapy : the journal of the American Society of Gene Therapy2021
Li JM, Yang DC, Oldham J, et al.
Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.Other primary literatureHumanActiveCancer medicine2021
Szlosarek PW, Wimalasingham AG, Phillips MM, et al.
Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor.Other primary literatureHuman & animalActiveNature communications2021
Zou Z, Hu X, Luo T, et al.
Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma.Other primary literatureHuman & animalActiveJournal of experimental & clinical cancer research : CR2021
Kim S, Lee M, Song Y, et al.
The prognostic and therapeutic implications of distinct patterns of argininosuccinate synthase 1 (ASS1) and arginase-2 (ARG2) expression by cancer cells and tumor stroma in non-small-cell lung cancer.Other primary literatureUnknownActiveCancer & metabolism2021
Giatromanolaki A, Harris AL, Koukourakis MI
Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.Other primary literatureHuman & animalActiveClinical cancer research : an official journal of the American Association for Cancer Research2020
Ji JX, Cochrane DR, Tessier-Cloutier B, et al.
Acid-Induced Downregulation of ASS1 Contributes to the Maintenance of Intracellular pH in Cancer.Other primary literatureHuman & animalActiveCancer research2019
Silberman A, Goldman O, Boukobza Assayag O, et al.
Argininosuccinate synthase 1 suppresses cancer cell invasion by inhibiting STAT3 pathway in hepatocellular carcinoma.Other primary literatureHuman & animalActiveActa biochimica et biophysica Sinica2019
Tao X, Zuo Q, Ruan H, et al.
Argininosuccinate Synthase 1 is a Metabolic Regulator of Colorectal Cancer Pathogenicity.Other primary literatureHumanActiveACS chemical biology2017
Bateman LA, Ku WM, Heslin MJ, et al.
Argininosuccinate Synthase 1-Deficiency Enhances the Cell Sensitivity to Arginine through Decreased DEPTOR Expression in Endometrial Cancer.Other primary literatureHumanActiveScientific reports2017
Ohshima K, Nojima S, Tahara S, et al.
Argininosuccinate synthase 1 is an intrinsic Akt repressor transactivated by p53.Other primary literatureHuman & animalActiveScience advances2017
Miyamoto T, Lo PHY, Saichi N, et al.
Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells.Other primary literatureHuman & animalActiveScience signaling2014
Qiu F, Chen YR, Liu X, et al.
ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.Other primary literatureHuman & animalActiveClinical cancer research : an official journal of the American Association for Cancer Research2013
Huang HY, Wu WR, Wang YH, et al.
Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells.Other primary literatureAnimalActiveAmerican journal of physiology. Heart and circulatory physiology2007
Goodwin BL, Pendleton LC, Levy MM, et al.
Induction of inducible nitric oxide synthase, argininosuccinate synthase, and GTP cyclohydrolase I in arthritic joints of human tumor necrosis factor-alpha transgenic mice.Other primary literatureHuman & animalActiveThe Journal of rheumatology2003
Hukkanen M, Platts LA, Haralambous S, et al.
Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic typeDesign not determinedUnknownUnknown
Ji JX, Cochrane DR, Tessier-Cloutier B, et al.
Argininosuccinate Synthase 1 Suppresses Tumor Progression Through Activation of PERK/eIF2α/ATF4/CHOP Axis in Hepatocellular CarcinomaDesign not determinedUnknownUnknown
Kim S, Lee M, Song Y, et al.